Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
12
12
12
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+8 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (12)
Showing 10 of 12 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Worked with same sponsors:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
David Avigan, MD
Beth Israel Deaconess Medical Center
Shared therapeutic areas:
Worked with same sponsors:
John D. Hainsworth, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Arnon Nagler, MD
Chaim Sheba Medical Center
Shared therapeutic areas:
Rahul Aggarwal, MD
University of California, San Francisco
Shared therapeutic areas:
Worked with same sponsors:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Roberto Hernández Martín, MD
Hospital Virgen de la Concha
Shared therapeutic areas:
Elena Pérez Ceballos, MD
Hospital Morales Meseguer
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (12)
Showing 12 of 12 trials
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
All 12 trials loaded